Wall Street analysts expect that Natera, Inc. (NASDAQ:NTRA) will post ($0.46) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Natera’s earnings, with the highest EPS estimate coming in at ($0.44) and the lowest estimate coming in at ($0.50). Natera reported earnings of ($0.50) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 8%. The business is expected to report its next earnings report on Wednesday, November 8th.

According to Zacks, analysts expect that Natera will report full-year earnings of ($2.02) per share for the current year, with EPS estimates ranging from ($2.08) to ($1.96). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.24) per share, with EPS estimates ranging from ($1.30) to ($1.18). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Natera.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, August 8th. The medical research company reported ($0.52) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.52). Natera had a negative return on equity of 137.46% and a negative net margin of 62.64%. The business had revenue of $53.60 million during the quarter, compared to analysts’ expectations of $50.57 million. During the same period in the prior year, the business earned ($0.46) EPS. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year.

A number of research analysts recently issued reports on NTRA shares. Zacks Investment Research lowered Natera from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Canaccord Genuity lifted their target price on Natera from $14.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, May 10th. ValuEngine lowered Natera from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. BidaskClub lowered Natera from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Finally, Morgan Stanley decreased their target price on Natera from $18.00 to $13.00 and set an “overweight” rating for the company in a report on Monday, August 7th. Four equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $14.45.

Shares of Natera (NTRA) traded down 0.2690% during midday trading on Monday, hitting $11.1599. The company had a trading volume of 214,724 shares. The company has a 50-day moving average of $9.95 and a 200 day moving average of $9.62. Natera has a 12 month low of $7.35 and a 12 month high of $12.95. The firm’s market capitalization is $593.96 million.

A number of hedge funds have recently made changes to their positions in NTRA. TIAA CREF Investment Management LLC increased its stake in Natera by 14.3% in the first quarter. TIAA CREF Investment Management LLC now owns 93,901 shares of the medical research company’s stock valued at $833,000 after buying an additional 11,743 shares during the last quarter. Principal Financial Group Inc. increased its stake in Natera by 0.6% in the first quarter. Principal Financial Group Inc. now owns 111,278 shares of the medical research company’s stock valued at $987,000 after buying an additional 688 shares during the last quarter. Spark Investment Management LLC purchased a new stake in Natera during the first quarter valued at $1,335,000. Alliancebernstein L.P. increased its stake in Natera by 5.6% in the first quarter. Alliancebernstein L.P. now owns 26,600 shares of the medical research company’s stock valued at $236,000 after buying an additional 1,400 shares during the last quarter. Finally, American International Group Inc. increased its stake in Natera by 7.1% in the first quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock valued at $142,000 after buying an additional 1,068 shares during the last quarter. 59.86% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/21/0-46-eps-expected-for-natera-inc-ntra-this-quarter.html.

Natera Company Profile

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.